- Home
- PSNL vs DNA Comparison
PSNL vs DNA Comparison
Compare PSNL & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- DNA
- Stock Information
- Founded
- PSNL 2011
- DNA 2008
- Country
- PSNL United States
- DNA United States
- Employees
- PSNL N/A
- DNA N/A
- Industry
- PSNL Medical Specialities
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSNL Health Care
- DNA Health Care
- Exchange
- PSNL Nasdaq
- DNA Nasdaq
- Market Cap
- PSNL 415.1M
- DNA 466.4M
- IPO Year
- PSNL 2019
- DNA N/A
- Fundamental
- Price
- PSNL $5.30
- DNA $7.60
- Analyst Decision
- PSNL Strong Buy
- DNA Sell
- Analyst Count
- PSNL 5
- DNA 3
- Target Price
- PSNL $8.00
- DNA $9.67
- AVG Volume (30 Days)
- PSNL 656.8K
- DNA 986.1K
- Earning Date
- PSNL 05-06-2025
- DNA 05-06-2025
- Dividend Yield
- PSNL N/A
- DNA N/A
- EPS Growth
- PSNL N/A
- DNA N/A
- EPS
- PSNL N/A
- DNA N/A
- Revenue
- PSNL $85,694,000.00
- DNA $237,417,000.00
- Revenue This Year
- PSNL $0.45
- DNA N/A
- Revenue Next Year
- PSNL $25.75
- DNA $15.91
- P/E Ratio
- PSNL N/A
- DNA N/A
- Revenue Growth
- PSNL 15.57
- DNA 13.76
- 52 Week Low
- PSNL $1.14
- DNA $5.00
- 52 Week High
- PSNL $7.20
- DNA $22.60
- Technical
- Relative Strength Index (RSI)
- PSNL 66.92
- DNA 52.05
- Support Level
- PSNL $4.47
- DNA $7.14
- Resistance Level
- PSNL $5.39
- DNA $7.78
- Average True Range (ATR)
- PSNL 0.31
- DNA 0.45
- MACD
- PSNL 0.01
- DNA 0.01
- Stochastic Oscillator
- PSNL 93.64
- DNA 58.12
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.